FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Gail Eckhardt

Research Profile

Disorders

Chemicals & Drugs

Concepts & Ideas

Procedures

Co-author Network

Publications

TOP 3
Jennifer Schlegel; Janiel M Shields; Aik Choon Tan; John J Tentler; Dimitri G Trembath; Xiaodong Wang; Amanda Winges; Chao Yang; Weihe Zhang; Ronald L Hamilton; Pei-Fen Kuan; Jing Liu; Bentley R Midkiff; C Ryan Miller; Stergios J Moschos; Nana Nikolaishvili-Feinberg; Maria J Sambade; Susan Sather; Craig C Carson; Deborah DeRyckere; Lyn M Duncan; H Shelton Earp; S Gail Eckhardt; Stephen V Frye; Douglas K Graham
MERTK receptor tyrosine kinase is a therapeutic target in melanoma.
Colin D Weekes; Glen J Weiss; Li-Tain Yeh; Alex A. Adjei; Ronald L Dubowy; Grace K Dy; S Gail Eckhardt; Lia Gore; Cory Iverson; Michael Jeffers; Diane P Leffingwell; Karl D Lewis; Wen W Ma; Jeffrey N Miner; Prabhu Rajagopalan; Ramesh K Ramanathan; Beth Sheedy; Zancong Shen; Daniel D Von Hoff; Neil J Clendeninn
Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer.
Timothy A Yap; Natalie J Serkova; James Spicer; Jennifer Spratlin; Andrew Stephens; Hendrik-Tobias Arkenau; Ramesh R Boinpally; Katie Brock; D Ross Camidge; Jon Chick; George Demetri; Nandita M deSouza; S Gail Eckhardt; Richard Gedrich; Suzanne George; Stephen J Gwyther; Stan B Kaye; Rohit Lal; Martin O Leach; Srinivasu Poondru; Michelle Scurr
First-in-human phase I trial of two schedules of OSI-930, a novel multikinase inhibitor, incorporating translational proof-of-mechanism studies.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Gail Eckhardt (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Jennifer Schlegel; Janiel M Shields; Aik Choon Tan; John J Tentler; Dimitri G Trembath; Xiaodong Wang; Amanda Winges; Chao Yang; Weihe Zhang; Ronald L Hamilton; Pei-Fen Kuan; Jing Liu; Bentley R Midkiff; C Ryan Miller; Stergios J Moschos; Nana Nikolaishvili-Feinberg; Maria J Sambade; Susan Sather; Craig C Carson; Deborah DeRyckere; Lyn M Duncan; H Shelton Earp; S Gail Eckhardt; Stephen V Frye; Douglas K Graham
MERTK receptor tyrosine kinase is a therapeutic target in melanoma.
The Journal of clinical investigation 2013;123(5):2257-67.
2013: Colin D Weekes; Glen J Weiss; Li-Tain Yeh; Alex A. Adjei; Ronald L Dubowy; Grace K Dy; S Gail Eckhardt; Lia Gore; Cory Iverson; Michael Jeffers; Diane P Leffingwell; Karl D Lewis; Wen W Ma; Jeffrey N Miner; Prabhu Rajagopalan; Ramesh K Ramanathan; Beth Sheedy; Zancong Shen; Daniel D Von Hoff; Neil J Clendeninn
Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2013;19(5):1232-43.
2013: Timothy A Yap; Natalie J Serkova; James Spicer; Jennifer Spratlin; Andrew Stephens; Hendrik-Tobias Arkenau; Ramesh R Boinpally; Katie Brock; D Ross Camidge; Jon Chick; George Demetri; Nandita M deSouza; S Gail Eckhardt; Richard Gedrich; Suzanne George; Stephen J Gwyther; Stan B Kaye; Rohit Lal; Martin O Leach; Srinivasu Poondru; Michelle Scurr
First-in-human phase I trial of two schedules of OSI-930, a novel multikinase inhibitor, incorporating translational proof-of-mechanism studies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2013;19(4):909-19.
2013: S L Davis; S Gail Eckhardt; W A Messersmith; Antonio Jimeno
The development of regorafenib and its current and potential future role in cancer therapy.
Drugs of today (Barcelona, Spain : 1998) 2013;49(2):105-15.
2013: Todd M Pitts; Heather M Selby; Anna Spreafico; Aik Choon Tan; John J Tentler; Marileila Varella-Garcia; John Arcaroli; Erica L Bradshaw-Pierce; Blair C Britt; Maria I Kachaeva; Gillian N Kulikowski; Kelly L McPhillips; Wells A Messersmith; Brion W Murray; S Gail Eckhardt
Association of the epithelial-to-mesenchymal transition phenotype with responsiveness to the p21-activated kinase inhibitor, PF-3758309, in colon cancer models.
Frontiers in pharmacology 2013;4():35.
2013: Erica L Bradshaw-Pierce; Daniel L Gustafson; Charles Halsey; Julie L C Kan; Nathan V Lee; Kelly McPhillips; Brion William Murray; Leslie Nguyen; Todd M Pitts; Aik Choon Tan; Mark West; S Gail Eckhardt
Tumor P-Glycoprotein Correlates with Efficacy of PF-3758309 in in vitro and in vivo Models of Colorectal Cancer.
Frontiers in pharmacology 2013;4():22.
2013: Erica L Bradshaw-Pierce; S Gail Eckhardt; Daniel L Gustafson; Gillian Kulikowski; Andrea L Merz; Todd M Pitts; Heather Selby; Natalie J Serkova; Colin D Weekes
Utilization of quantitative in vivo pharmacology approaches to assess combination effects of everolimus and irinotecan in mouse xenograft models of colorectal cancer.
PloS one 2013;8(3):e58089.
2013: Jennifer R Diamond; S Gail Eckhardt; Graham C Fletcher; Maria I Kachaeva; Timothy P Newton; Todd M Pitts; Heather M Selby; Aik Choon Tan; Mark R Bray; Kelsey L Brunkow; Marileila Varella-Garcia; John J Tentler
Predictive biomarkers of sensitivity to the aurora and angiogenic kinase inhibitor ENMD-2076 in preclinical breast cancer models.
Clinical cancer research : an official journal of the American Association for Cancer Research 2013;19(1):291-303.
2012: Harvey Wong; Ron Yu; Elizabeth Blackwood; Nageshwar R Budha; Iris T Chan; Walter C Darbonne; S Gail Eckhardt; Rebecca Erickson; John A Flygare; Stephen E Gould; Cornelis E A C Hop; Patricia M LoRusso; Michael Mamounas; Ronald Steigerwalt; Andrew Wagner; Joseph A Ware; Kristina West; Wayne J Fairbrother
Dogs are more sensitive to antagonists of inhibitor of apoptosis proteins than rats and humans: a translational toxicokinetic/toxicodynamic analysis.
Toxicological sciences : an official journal of the Society of Toxicology 2012;130(1):205-13.
2012: Lia Gore; S Grolnic; J Li; S L Moulder-Thompson; Cindy L O'Bryant; E Rivera; Michele Basche; D Cleere; Y A Elsayed; S Eppers; S Gail Eckhardt
Phase I combination study of trabectedin and capecitabine in patients with advanced malignancies.
Investigational new drugs 2012;30(5):1942-9.
2012: David S Hong; Daniel W Bowles; S Gail Eckhardt; Gerald S Falchook; Goldy C George; Diana F Hausman; Roy S Herbst; Kevin Klucher; Razelle Kurzrock; Wells A Messersmith; Cindy L O'Bryant; Scott Peterson; Alex C H Vo; Antonio Jimeno
A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(15):4173-82.
2012: Kelly D Sullivan; Aik Choon Tan; John J Tentler; James DeGregori; S Gail Eckhardt; Ryan E Henry; Jihye Kim; Nuria Padilla-Just; Christopher C Porter; Joaquín Maximiliano Espinosa
ATM and MET kinases are synthetic lethal with nongenotoxic activation of p53.
Nature chemical biology 2012;8(7):646-54.
2012: S Leong; X Lin; Wells A Messersmith; J Spratlin; D Ross Camidge; E Chan; E Chow Maneval; S Diab; S Gail Eckhardt; R Khosravan; A C Lockhart
A phase I study of sunitinib combined with modified FOLFOX6 in patients with advanced solid tumors.
Cancer chemotherapy and pharmacology 2012;70(1):65-74.
2012: John J Tentler; Colin D Weekes; John Arcaroli; Antonio Jimeno; Stephen Leong; Wells A Messersmith; Todd M Pitts; Aik Choon Tan; S Gail Eckhardt
Patient-derived tumour xenografts as models for oncology drug development.
Nature reviews. Clinical oncology 2012;9(6):338-50.
2012: John Arcaroli; Lynne Bemis; Arvind Dasari; S Gail Eckhardt; Todd M Pitts; Rebecca W Powell; Kevin S Quackenbush; Jaclyn M Reinemann; Anna Spreafico; Aik Choon Tan; Basel M Touban; Marileila Varella-Garcia; Wells A Messersmith
Common PIK3CA mutants and a novel 3' UTR mutation are associated with increased sensitivity to saracatinib.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(9):2704-14.
2012: Brian L Harry; S Gail Eckhardt; Antonio Jimeno
JAK2 inhibition for the treatment of hematologic and solid malignancies.
Expert opinion on investigational drugs 2012;21(5):637-55.
2012: Wen Wee Ma; Manoj Maniar; Wells A Messersmith; Chen Ren; Colin D Weekes; Amy Whitworth; Francois Wilhelm; Alex A. Adjei; Grace K Dy; S Gail Eckhardt; Antonio Jimeno
Phase I study of Rigosertib, an inhibitor of the phosphatidylinositol 3-kinase and Polo-like kinase 1 pathways, combined with gemcitabine in patients with solid tumors and pancreatic cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(7):2048-55.
2012: M Pia Morelli; Sujatha Nallapareddy; Todd M Pitts; Natalie J Serkova; Aik Choon Tan; John J Tentler; John J Arcaroli; Erica L Bradshaw-Pierce; Amy M Brown; Fortunato Ciardiello; Manuel Hidalgo; Gillian N Kulikowski; S Gail Eckhardt
Preclinical activity of the rational combination of selumetinib (AZD6244) in combination with vorinostat in KRAS-mutant colorectal cancer models.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(4):1051-62.
2011: Donna Niedzwiecki; Mark O'Rourke; Michael C Perry; J Marc Pipas; Gity N Porjosh; Philippe Rougier; Joel H Schwartz; Robert S Warren; Steven Alberts; James Atkins; Al Bowen Benson; Monica M Bertagnolli; Carolyn Corlies Compton; S Gail Eckhardt; Anthony Fields; Richard M Goldberg; Nancy E Kemeny; David J Kerr; Robert J Mayer; Thomas A Colacchio
Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: results from CALGB 9581.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(23):3146-52.
2011: Jennifer Spratlin; T M Pitts; G N Kulikowski; M P Morelli; John J Tentler; N J Serkova; S Gail Eckhardt
Synergistic activity of histone deacetylase and proteasome inhibition against pancreatic and hepatocellular cancer cell lines.
Anticancer research 2011;31(4):1093-103.
2011: Qing Zhou; Daniel Gustafson; Sujatha Nallapareddy; Sami Diab; Stephen Leong; Karl Lewis; Lia Gore; Wells A Messersmith; Anthony M Treston; S Gail Eckhardt; Carolyn Sidor; D Ross Camidge
A phase I dose-escalation, safety and pharmacokinetic study of the 2-methoxyestradiol analog ENMD-1198 administered orally to patients with advanced cancer.
Investigational new drugs 2011;29(2):340-6.
2011: Pasi A Janne; David S Boss; D Ross Camidge; Carolyn D Britten; Jeffrey A Engelman; Edward B Garon; Feng Guo; Steven Wong; Jane Liang; Stephen Letrent; Robert Millham; Ian Taylor; S Gail Eckhardt; Jan H M Schellens
Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(5):1131-9.
2011: Jennifer R Diamond; Bruno R Bastos; Ryan J Hansen; Daniel L Gustafson; S Gail Eckhardt; Eunice L Kwak; Shuchi S Pandya; Graham C Fletcher; Todd M Pitts; Gillian N Kulikowski; Mark Morrow; Jamie Arnott; Mark R Bray; Carolyn Sidor; Wells A Messersmith; Geoffrey I Shapiro
Phase I safety, pharmacokinetic, and pharmacodynamic study of ENMD-2076, a novel angiogenic and Aurora kinase inhibitor, in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(4):849-60.
2010: John J Tentler; Sujatha Nallapareddy; Aik Choon Tan; Anna Spreafico; Todd M Pitts; M Pia Morelli; Heather M Selby; Maria I Kachaeva; Sara A Flanigan; Gillian N Kulikowski; Stephen Leong; John J Arcaroli; Wells A Messersmith; S Gail Eckhardt
Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancer.
Molecular cancer therapeutics 2010;9(12):3351-62.
2010: Sara A Flanigan; Todd M Pitts; S Gail Eckhardt; John J Tentler; Aik Choon Tan; Andrew Thorburn; Stephen Leong
The insulin-like growth factor I receptor/insulin receptor tyrosine kinase inhibitor PQIP exhibits enhanced antitumor effects in combination with chemotherapy against colorectal cancer models.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(22):5436-46.
2010: Erika Martinelli; Teresa Troiani; Floriana Morgillo; Gabriella Rodolico; Donata Vitagliano; Maria Pia Morelli; Concetta Tuccillo; Loredana Vecchione; Anna Capasso; Michele Orditura; Ferdinando De Vita; S Gail Eckhardt; Massimo Santoro; Liberato Berrino; Fortunato Ciardiello
Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(20):4990-5001.
2010: Thomas J Pugh; Changhu Chen; Rachel Rabinovitch; S Gail Eckhardt; Kyle E Rusthoven; Robyn Swing; David Raben
Phase I trial of bortezomib and concurrent external beam radiation in patients with advanced solid malignancies.
International journal of radiation oncology, biology, physics 2010;78(2):521-6.
2010: John J Arcaroli; Basel M Touban; Aik Choon Tan; Marileila Varella-Garcia; Rebecca W Powell; S Gail Eckhardt; Paul Elvin; Dexiang Gao; Wells A Messersmith
Gene array and fluorescence in situ hybridization biomarkers of activity of saracatinib (AZD0530), a Src inhibitor, in a preclinical model of colorectal cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(16):4165-77.
2010: Todd M Pitts; Aik Choon Tan; Gillian N Kulikowski; John J Tentler; Amy M Brown; Sara A Flanigan; Stephen Leong; Christopher D Coldren; Fred R Hirsch; Marileila Varella-Garcia; Christopher Korch; S Gail Eckhardt
Development of an integrated genomic classifier for a novel agent in colorectal cancer: approach to individualized therapy in early development.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(12):3193-204.
2010: Roy S Herbst; S Gail Eckhardt; Razelle Kurzrock; Scot W Ebbinghaus; Peter J O'Dwyer; Michael S Gordon; William Novotny; Meredith A Goldwasser; Tanyifor M Tohnya; Bert L Lum; Avi Ashkenazi; Adrian M Jubb; David S Mendelson
Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(17):2839-46.
2010: John J Tentler; Erica L Bradshaw-Pierce; Natalie J Serkova; Kendra M Hasebroock; Todd M Pitts; Jennifer R Diamond; Graham C Fletcher; Mark R Bray; S Gail Eckhardt
Assessment of the in vivo antitumor effects of ENMD-2076, a novel multitargeted kinase inhibitor, against primary and cell line-derived human colorectal cancer xenograft models.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(11):2989-98.
2010: Stephen Leong; Wells A Messersmith; Aik Choon Tan; S Gail Eckhardt
Novel agents in the treatment of metastatic colorectal cancer.
Cancer journal (Sudbury, Mass.) 2010;16(3):273-82.
2010: Razelle Kurzrock; Amita Patnaik; Joseph Aisner; Terri Warren; Stephen Leong; Robert Benjamin; S Gail Eckhardt; Joseph E Eid; Gerard Greig; Kai Habben; Cinara D McCarthy; Lia Gore
A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(8):2458-65.
2010: Udai Banerji; D Ross Camidge; Hendrik Verheul; Roshan Agarwal; Debashis Sarker; Stan B Kaye; Ingrid M E Desar; Johanna N H Timmer-Bonte; S Gail Eckhardt; Karl D Lewis; Kathryn H Brown; Mireille V Cantarini; Clive Morris; Sarah George; Paul D Smith; Carla M L van Herpen
The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(5):1613-23.
2010: Susan F Hudachek; S Gail Eckhardt; Barbara Hicks; Daniel L Gustafson
Population pharmacokinetic model of PI-88, a heparanase inhibitor.
Cancer chemotherapy and pharmacology 2010;65(4):743-53.
2010: D Ross Camidge; Roy S Herbst; Michael S Gordon; S Gail Eckhardt; Razelle Kurzrock; Blythe Durbin; Josephine Ing; Tanyifor M Tohnya; Jason Sager; Avi Ashkenazi; Gordon Bray; David Mendelson
A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(4):1256-63.
2010: Jennifer L Spratlin; Roger B Cohen; Matthew Eadens; Lia Gore; D Ross Camidge; Sami Diab; Stephen Leong; Cindy O'Bryant; Laura Q M Chow; Natalie J Serkova; Neal J Meropol; Nancy L Lewis; E Gabriela Chiorean; Floyd Fox; Hagop Youssoufian; Eric K Rowinsky; S Gail Eckhardt
Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(5):780-7.
2010: Michael S Gordon; Christopher S Sweeney; David S Mendelson; S Gail Eckhardt; Abraham Anderson; Darrin M Beaupre; Daniel Branstetter; Teresa L Burgess; Angela Coxon; Hongjie Deng; Paula Kaplan-Lefko; Ian M Leitch; Kelly S Oliner; Lucy Yan; Min Zhu; Lia Gore
Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(2):699-710.
2009: Jennifer R Diamond; Virginia F Borges; S Gail Eckhardt; Antonio Jimeno
BRCA in breast cancer: from risk assessment to therapeutic prediction.
Drug news & perspectives 2009;22(10):603-8.
2009: Stephen Leong; Roger B Cohen; Daniel L Gustafson; Corey J Langer; D Ross Camidge; Kristin Padavic; Lia Gore; Margaret Smith; Laura Q Chow; Margaret von Mehren; Cindy O'Bryant; Sujatha Hariharan; Sami Diab; Norma Lynn Fox; Renée Miceli; S Gail Eckhardt
Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(26):4413-21.
2009: M Pia Morelli; Amy M Brown; Todd M Pitts; John J Tentler; Fortunato Ciardiello; Anderson Ryan; Juliane M Jürgensmeier; S Gail Eckhardt
Targeting vascular endothelial growth factor receptor-1 and -3 with cediranib (AZD2171): effects on migration and invasion of gastrointestinal cancer cell lines.
Molecular cancer therapeutics 2009;8(9):2546-58.
2009: Jost Klawitter; Douglas J Kominsky; Jaimi L Brown; Jost Klawitter; Uwe Christians; Dieter Leibfritz; Junia V Melo; S Gail Eckhardt; Natalie J Serkova
Metabolic characteristics of imatinib resistance in chronic myeloid leukaemia cells.
British journal of pharmacology 2009;158(2):588-600.
2009: Douglas J Kominsky; Jelena Klawitter; Jaimi L Brown; Laszlo G Boros; Junia V Melo; S Gail Eckhardt; Natalie J Serkova
Abnormalities in glucose uptake and metabolism in imatinib-resistant human BCR-ABL-positive cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(10):3442-50.
2009: CC Olsen; Tracey E Schefter; Honglin Chen; Madeleine Kane; Stephen Leong; Martin D McCarter; Yang Chen; Philip C Mack; S Gail Eckhardt; Gregory V Stiegmann; David Raben
Results of a phase I trial of 12 patients with locally advanced pancreatic carcinoma combining gefitinib, paclitaxel, and 3-dimensional conformal radiation: report of toxicity and evaluation of circulating K-ras as a potential biomarker of response to therapy.
American journal of clinical oncology 2009;32(2):115-21.
2009: J Klawitter; N Anderson; J Klawitter; Uwe Christians; Dieter Leibfritz; S Gail Eckhardt; Natalie J Serkova
Time-dependent effects of imatinib in human leukaemia cells: a kinetic NMR-profiling study.
British journal of cancer 2009;100(6):923-31.
2009: Antonio Jimeno; Wells A Messersmith; Fred R Hirsch; Wilbur A Franklin; S Gail Eckhardt
KRAS mutations and susceptibility to cetuximab and panitumumab in colorectal cancer.
Cancer journal (Sudbury, Mass.) 2009;15(2):110-3.
2009: Antonio Jimeno; Wells A Messersmith; Fred R Hirsch; Wilbur A Franklin; S Gail Eckhardt
KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(7):1130-6.
2009: Todd M Pitts; Mark Morrow; Sara A Kaufman; John J Tentler; S Gail Eckhardt
Vorinostat and bortezomib exert synergistic antiproliferative and proapoptotic effects in colon cancer cell models.
Molecular cancer therapeutics 2009;8(2):342-9.
2009: S Gail Eckhardt; Peter De Porre; David Smith; Joan Maurel; William P Steward; Olivier Bouche; Helgi van de Velde; Bart Michiels; Roland Bugat
Patient-reported outcomes as a component of the primary endpoint in a double-blind, placebo-controlled trial in advanced pancreatic cancer.
Journal of pain and symptom management 2009;37(2):135-43.
2009: Jennifer L Spratlin; Natalie J Serkova; S Gail Eckhardt
Clinical applications of metabolomics in oncology: a review.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(2):431-40.
2008: Laura Q M Chow; Daniel L Gustafson; Cindy L O'Bryant; Lia Gore; Michele Basche; Scott N Holden; Mark C Morrow; Stacy Grolnic; Brian R Creese; Kaye L Roberts; Kat Davis; Russell Addison; S Gail Eckhardt
A phase I pharmacological and biological study of PI-88 and docetaxel in patients with advanced malignancies.
Cancer chemotherapy and pharmacology 2008;63(1):65-74.
2008: Laura Q M Chow; S Gail Eckhardt; Cindy L O'Bryant; Mary Kay Schultz; Mark Morrow; Stacy Grolnic; Michele Basche; Lia Gore
A phase I safety, pharmacological, and biological study of the farnesyl protein transferase inhibitor, lonafarnib (SCH 663366), in combination with cisplatin and gemcitabine in patients with advanced solid tumors.
Cancer chemotherapy and pharmacology 2008;62(4):631-46.
2008: Laura K Zerbe; Lori D Dwyer-Nield; Jason M Fritz; Elizabeth F Redente; Robert J Shroyer; Elizabeth Conklin; Shawn Kane; Chris Tucker; S Gail Eckhardt; Daniel L Gustafson; Kenneth K Iwata; Alvin M Malkinson
Inhibition by erlotinib of primary lung adenocarcinoma at an early stage in male mice.
Cancer chemotherapy and pharmacology 2008;62(4):605-20.
2008: Robert W Chen; Lynne Bemis; Carol M Amato; Han Myint; Hung Tran; Diane K Birks; S Gail Eckhardt; William A Robinson
Truncation in CCND1 mRNA alters miR-16-1 regulation in mantle cell lymphoma.
Blood 2008;112(3):822-9.
2008: Avi Ashkenazi; Pamela Holland; S Gail Eckhardt
Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(21):3621-30.
2008: Lia Gore; Mace L Rothenberg; Cindy L O'Bryant; Mary Kay Schultz; Alan B Sandler; Denise Coffin; Candice McCoy; Astrid Schott; Catherine Scholz; S Gail Eckhardt
A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(14):4517-25.
2008: Michele Basche; Anna E Barón; S Gail Eckhardt; Lodovico Balducci; Martha Persky; Adrah Levin; Nathaniel Jackson; Chan Zeng; Pamela Vranas; John F Steiner
Barriers to enrollment of elderly adults in early-phase cancer clinical trials.
Journal of oncology practice / American Society of Clinical Oncology 2008;4(4):162-8.
2008: Alex A. Adjei; Roger B Cohen; Wilbur Franklin; Clive Morris; David Wilson; Julian R Molina; Lorelei J Hanson; Lia Gore; Laura Chow; Stephen Leong; Lara Maloney; Gilad Gordon; Heidi Simmons; Allison Marlow; Kevin Litwiler; Suzy Brown; Gregory Poch; Katie Kane; Jerry Haney; S Gail Eckhardt
Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(13):2139-46.
2007: Natalie J Serkova; Jennifer L Spratlin; S Gail Eckhardt
NMR-based metabolomics: translational application and treatment of cancer.
Current opinion in molecular therapeutics 2007;9(6):572-85.
2007: Teresa Troiani; Natalie J Serkova; Daniel L Gustafson; Thomas K Henthorn; Owen Lockerbie; Andrea Merz; Michael Long; Mark Morrow; Fortunato Ciardiello; S Gail Eckhardt
Investigation of two dosing schedules of vandetanib (ZD6474), an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, in combination with irinotecan in a human colon cancer xenograft model.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(21):6450-8.
2007: Changhu Chen; Madeleine Kane; John Song; John P Campana; Adam Raben; Kenneth Hu; Louis B Harrison; Harry Quon; Janet Dancey; Anna Baron; Sherif Said; S Gail Eckhardt; David Raben
Phase I trial of gefitinib in combination with radiation or chemoradiation for patients with locally advanced squamous cell head and neck cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(31):4880-6.
2007: Leonard B Saltz; Lee S Rosen; John L Marshall; Robert J Belt; Herbert I Hurwitz; S Gail Eckhardt; Emily Bergsland; Daniel G Haller; A Craig Lockhart; Caio Rocha Lima; Xin Huang; Samuel E DePrimo; Edna Chow-Maneval; Richard C Chao; Heinz J Lenz
Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(30):4793-9.
2007: Yehuda Z Patt; Fa-Chyi Lee; James E Liebmann; Dimitrios Diamandidis; S Gail Eckhardt; Milind Javle; Glen R Justice; Wayne Keiser; Joseph R Salvatore; Alice Bexon; Edward Lin
Capecitabine plus 3-weekly irinotecan (XELIRI regimen) as first-line chemotherapy for metastatic colorectal cancer: phase II trial results.
American journal of clinical oncology 2007;30(4):350-7.
2007: S Hariharan; D Gustafson; Scott N Holden; D McConkey; D Davis; Mark Morrow; Michele Basche; Lia Gore; C Zang; Cindy L O'Bryant; Anna Baron; D Gallemann; D Colevas; S Gail Eckhardt
Assessment of the biological and pharmacological effects of the alpha nu beta3 and alpha nu beta5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007;18(8):1400-7.
2007: Peter J O'Dwyer; S Gail Eckhardt; Daniel G Haller; Joel E Tepper; Dennis J Ahnen; Stanley Hamilton; Al B Benson; Mace Rothenberg; Nicholas Petrelli; Heinz-Josef Lenz; Robert B Diasio; Raymond DuBois; Daniel Sargent; Jeff Sloan; C Daniel Johnson; Robert L Comis; Michael J O'Connell
Priorities in colorectal cancer research: recommendations from the Gastrointestinal Scientific Leadership Council of the Coalition of Cancer Cooperative Groups.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(16):2313-21.
2007: Erica L Bradshaw-Pierce; S Gail Eckhardt; Daniel L Gustafson
A physiologically based pharmacokinetic model of docetaxel disposition: from mouse to man.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(9):2768-76.
2007: Alberto Chiappori; S Gail Eckhardt; Ronald Bukowski; Daniel M Sullivan; Minoru Ikeda; Yoshitaka Yano; Takuko Yamada-Sawada; Yoshikaze Kambayashi; Kazushige Tanaka; Milind Javle; Tarek Mekhail; Cindy L O'Bryant; Patrick J Creaven
A phase I pharmacokinetic and pharmacodynamic study of s-3304, a novel matrix metalloproteinase inhibitor, in patients with advanced and refractory solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(7):2091-9.
2007: Laura Q M Chow; S Gail Eckhardt
Sunitinib: from rational design to clinical efficacy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(7):884-96.
2006: D Ross Camidge; S Gail Eckhardt; Lia Gore
Dynamic and modern: bringing the ethics of phase I trials up to date.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(32):5178-9; author reply 5179-80.
2006: Wells A Messersmith; Manuel Hidalgo; Michael A Carducci; S Gail Eckhardt
Novel targets in solid tumors: MEK inhibitors.
Clinical advances in hematology & oncology : H&O 2006;4(11):831-6.
2006: Lia Gore; Scott N Holden; R B Cohen; Mark Morrow; A Scott Pierson; Cindy L O'Bryant; M Persky; D Gustafson; C Mikule; S Zhang; P A Palmer; S Gail Eckhardt
A phase I safety, pharmacological and biological study of the farnesyl protein transferase inhibitor, tipifarnib and capecitabine in advanced solid tumors.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17(11):1709-17.
2006: Ghassan K Abou-Alfa; Richard Letourneau; Graydon Harker; Manuel Modiano; Herbert I Hurwitz; Nerses Simon Tchekmedyian; Kevie Feit; Judie Ackerman; Robert L De Jager; S Gail Eckhardt; Eileen O'Reilly
Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(27):4441-7.
2006: Michele Basche; Daniel L Gustafson; Scott N Holden; Cindy L O'Bryant; Lia Gore; Samir E Witta; Mary Kay Schultz; Mark Morrow; Adrah Levin; Brian R Creese; Michael Kangas; Kaye Roberts; Thu Nguyen; Kat Davis; Russell S Addison; Jane C Moore; S Gail Eckhardt
A phase I biological and pharmacologic study of the heparanase inhibitor PI-88 in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(18):5471-80.
2006: Maria Pia Morelli; Tina Cascone; Teresa Troiani; Concetta Tuccillo; Roberto Bianco; Nicola Normanno; Marco Romano; Bianca Maria Veneziani; Gabriella Fontanini; S Gail Eckhardt; Sabino De Pacido; Giampaolo Tortora; Fortunato Ciardiello
Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases.
Journal of cellular physiology 2006;208(2):344-53.
2006: Teresa Troiani; Owen Lockerbie; Mark Morrow; Fortunato Ciardiello; S Gail Eckhardt
Sequence-dependent inhibition of human colon cancer cell growth and of prosurvival pathways by oxaliplatin in combination with ZD6474 (Zactima), an inhibitor of VEGFR and EGFR tyrosine kinases.
Molecular cancer therapeutics 2006;5(7):1883-94.
2006: Lisa J Green; Philip Marder; Chad Ray; Carolyn A Cook; Susan Jaken; Luna Musib; Roy S Herbst; Michael A Carducci; Carolyn D Britten; Michele Basche; S Gail Eckhardt; Donald Thornton
Development and validation of a drug activity biomarker that shows target inhibition in cancer patients receiving enzastaurin, a novel protein kinase C-beta inhibitor.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(11 Pt 1):3408-15.
2006: Bhuvaneswari Ramaswamy; Anthony D Elias; Nicole Kelbick; Angela Dodley; Mark Morrow; Marsha Hauger; Joan Allen; Chris A Rhoades; Kari Kendra; Helen X Chen; S Gail Eckhardt; Charles L Shapiro
Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(10):3124-9.
2006: Anthony W Tolcher; Desiree Hao; Johann S de Bono; Alex Miller; Amita Patnaik; Lisa A Hammond; Leslie Ann Smetzer; Jill van Wart Hood; James Merritt; Eric K Rowinsky; Chris H Takimoto; Daniel Von Hoff; S Gail Eckhardt
Phase I, pharmacokinetic, and pharmacodynamic study of intravenously administered Ad5CMV-p53, an adenoviral vector containing the wild-type p53 gene, in patients with advanced cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(13):2052-8.
2005: Hiroyuki Kobayashi; S Gail Eckhardt; Jennifer A Lockridge; Mace L Rothenberg; Alan B Sandler; Cindy L O'Bryant; Wendy Cooper; Scott N Holden; Roger D Aitchison; Nassim Usman; Maurice Wolin; Michele L Basche
Safety and pharmacokinetic study of RPI.4610 (ANGIOZYME), an anti-VEGFR-1 ribozyme, in combination with carboplatin and paclitaxel in patients with advanced solid tumors.
Cancer chemotherapy and pharmacology 2005;56(4):329-36.
2005: Ghassan K Abou-Alfa; Eric K Rowinsky; Yehuda Z Patt; Gary K Schwartz; David P Kelsen; Sunil Sharma; Eve Siegel; Carlos R Becerra; S Gail Eckhardt; Kevie Feit; Robert L De Jager; Eileen O'Reilly
A Phase II study of intravenous exatecan administered daily for 5 days, every 3 weeks to patients with biliary tract cancers.
American journal of clinical oncology 2005;28(4):334-9.
2005: Scott N Holden; S Gail Eckhardt; Russell L Basser; Richard de Boer; D Rischin; M Green; Mark A Rosenthal; C Wheeler; Alan Barge; Herbert I Hurwitz
Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16(8):1391-7.
2005: Maria Pia Morelli; Tina Cascone; Teresa Troiani; Ferdinando De Vita; Michele Orditura; Gianluca Laus; S Gail Eckhardt; Stefano Pepe; Giampaolo Tortora; Fortunato Ciardiello
Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16 Suppl 4():iv61-68.
2004: Mark J Ratain; S Gail Eckhardt
Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(22):4442-5.
2004: Samir E Witta; Daniel L Gustafson; A Scott Pierson; Alexander Menter; Scott N Holden; Michele Basche; Martha Persky; Cindy L O'Bryant; Chan Zeng; Anna Baron; Michael E Long; Amy Gibbs; Karen Kelly; Paul A Bunn; Daniel C Chan; Patrick Pallansch; S Gail Eckhardt
A phase I and pharmacokinetic study of exisulind and docetaxel in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(21):7229-37.
2004: Sven Gottschalk; Nora Anderson; Carsten Hainz; S Gail Eckhardt; Natalie J Serkova
Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(19):6661-8.
2004: Samira Syed; Chris H Takimoto; Manuel Hidalgo; Jinee Rizzo; John Kuhn; Lisa A Hammond; Garry Schwartz; Anthony W Tolcher; Amita Patnaik; S Gail Eckhardt; Eric K Rowinsky
A phase I and pharmacokinetic study of Col-3 (Metastat), an oral tetracycline derivative with potent matrix metalloproteinase and antitumor properties.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(19):6512-21.
2003: Amita Patnaik; S Gail Eckhardt; Elzbieta Izbicka; Anthony A Tolcher; Lisa A Hammond; Chris H Takimoto; Garry Schwartz; Heather McCreery; Andrew Goetz; Masataka Mori; Kazutoyo Terada; Lou Gentner; Mary-Ellen Rybak; Henry Richards; Steven Zhang; Eric K Rowinsky
A phase I, pharmacokinetic, and biological study of the farnesyltransferase inhibitor tipifarnib in combination with gemcitabine in patients with advanced malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(13):4761-71.
2003: Daniel L Gustafson; Michael E Long; Joseph A Zirrolli; Mark W Duncan; Scott N Holden; A Scott Pierson; S Gail Eckhardt
Analysis of docetaxel pharmacokinetics in humans with the inclusion of later sampling time-points afforded by the use of a sensitive tandem LCMS assay.
Cancer chemotherapy and pharmacology 2003;52(2):159-66.
2003: Desirée Hao; Lisa A Hammond; S Gail Eckhardt; Amita Patnaik; Chris H Takimoto; Garry H Schwartz; Andrew D Goetz; Anthony W Tolcher; Heather McCreery; Khalid Mamun; Jon I Williams; Kenneth J Holroyd; Eric K Rowinsky
A Phase I and pharmacokinetic study of squalamine, an aminosterol angiogenesis inhibitor.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(7):2465-71.
2002: A Scott Pierson; Peter Gibbs; Jon Richards; Paul Russ; S Gail Eckhardt; Rene Gonzalez
A phase II study of Irofulven (MGI 114) in patients with stage IV melanoma.
Investigational new drugs 2002;20(3):357-62.
2002: Lillian L Siu; Eric K Rowinsky; Lisa A Hammond; Geoffrey R Weiss; Manuel Hidalgo; Gary M Clark; Judy Moczygemba; Les Choi; Ron Linnartz; Nicholas C Barbet; Ivo Sklenar; Renaud Capdeville; Gregory Gan; Carl W Porter; Daniel Von Hoff; S Gail Eckhardt
A phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with Advanced solid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(7):2157-66.
2002: Amita Patnaik; Eric K Rowinsky; Miguel A Villalona; Lisa A Hammond; Carolyn D Britten; Lillian L Siu; Andrew Goetz; Sally A Felton; Susan Burton; Frank H Valone; S Gail Eckhardt
A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(7):2142-8.
2002: Roy S Herbst; Manuel Hidalgo; A Scott Pierson; Scott N Holden; Michael Bergen; S Gail Eckhardt
Angiogenesis inhibitors in clinical development for lung cancer.
Seminars in oncology 2002;29(1 Suppl 4):66-77.
2002: Anthony J Murgo; Janet E Dancey; S Gail Eckhardt; Manuel Hidalgo; Arbuck Susan; Kenn Zerivitz; Barbara A Blaylock
New targets for cancer chemotherapy.
Cancer chemotherapy and biological response modifiers 2002;20():239-72.
2002: Miguel A Villalona-Calero; S Gail Eckhardt; Geoffrey Weiss; Manuel Hidalgo; Jos H Beijnen; Charlotte van Kesteren; Hilde Rosing; Elizabeth Campbell; Maura Kraynak; Luis Lopez-Lazaro; Cecilia Guzman; Daniel Von Hoff; José Jimeno; Eric K Rowinsky
A phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(1):75-85.
2001: Mace L Rothenberg; John Kuhn; L J Schaaf; Gladys I Rodriguez; S Gail Eckhardt; Miguel A Villalona-Calero; David A Rinaldi; Lisa A Hammond; S Hodges; A Sharma; Gary L Elfring; R G Petit; Paula K Locker; Langdon L Miller; Daniel Von Hoff
Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2001;12(11):1631-41.
2001: Robert H Vonderheide; Janice P Dutcher; J E Anderson; S Gail Eckhardt; Katherine Stephans; B Razvillas; Susan Garl; M D Butine; V P Perry; R J Armitage; RG Ghalie; D A Caron; John G Gribben
Phase I study of recombinant human CD40 ligand in cancer patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(13):3280-7.
2001: Manuel Hidalgo; Lillian L Siu; J Nemunaitis; Jinee Rizzo; Lisa A Hammond; Chris H Takimoto; S Gail Eckhardt; Anthony W Tolcher; Carolyn D Britten; Louis Denis; K Ferrante; Daniel Von Hoff; S Silberman; Eric K Rowinsky
Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(13):3267-79.
2001: Anthony W Tolcher; S Gail Eckhardt; John Kuhn; L Hammond; Geoffrey Weiss; Jinee Rizzo; Cheryl Aylesworth; Manuel Hidalgo; Amita Patnaik; Garry Schwartz; Sally A Felton; Elizabeth Campbell; Eric K Rowinsky
Phase I and pharmacokinetic study of NSC 655649, a rebeccamycin analog with topoisomerase inhibitory properties.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(11):2937-47.
2001: Manuel Hidalgo; S Gail Eckhardt
Development of matrix metalloproteinase inhibitors in cancer therapy.
Journal of the National Cancer Institute 2001;93(3):178-93.
2001: Manuel Hidalgo; A Scott Pierson; S N Holden; M Bergen; S Gail Eckhardt
Therapeutic angiogenesis inhibitors in the treatment of cancer.
Advances in internal medicine 2001;47():159-90.
2000: S Gail Eckhardt; Sharyn D Baker; Carolyn D Britten; Manuel Hidalgo; Lillian Siu; Lisa A Hammond; Miguel A Villalona-Calero; Sally A Felton; Ronald L Drengler; John Kuhn; Gary M Clark; S L Smith; John R MacDonald; C Smith; Judy Moczygemba; Steven D Weitman; Daniel Von Hoff; Eric K Rowinsky
Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(24):4086-97.
2000: Amita Patnaik; Eric K Rowinsky; B K Tammara; Manuel Hidalgo; Ronald L Drengler; A M Garner; Lillian L Siu; Lisa A Hammond; Sally A Felton; S Mallikaarjun; Daniel Von Hoff; S Gail Eckhardt
Phase I and pharmacokinetic study of the differentiating agent vesnarinone in combination with gemcitabine in patients with advanced cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(23):3974-85.
2000: Lisa A Hammond; Susan G Hilsenbeck; S Gail Eckhardt; Jennifer Marty; Gina L Mangold; John R MacDonald; Eric K Rowinsky; Daniel Von Hoff; Steven D Weitman
Enhanced antitumour activity of 6-hydroxymethylacylfulvene in combination with topotecan or paclitaxel in the MV522 lung carcinoma xenograft model.
European journal of cancer (Oxford, England : 1990) 2000;36(18):2430-6.
2000: Eric K Rowinsky; T R Johnson; Charles E Geyer; Lisa A Hammond; S Gail Eckhardt; Ronald L Drengler; Leslie Ann Smetzer; John Coyle; Jinee Rizzo; Garry Schwartz; Anthony W Tolcher; Daniel Von Hoff; Robert L De Jager
DX-8951f, a hexacyclic camptothecin analog, on a daily-times-five schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(17):3151-63.
2000: Carolyn D Britten; Eric K Rowinsky; Sharyn D Baker; Geoffrey R Weiss; Lon Smith; Joseph Stephenson; M Rothenberg; Leslie Ann Smetzer; J Cramer; W Collins; Daniel Von Hoff; S Gail Eckhardt
A phase I and pharmacokinetic study of the mitochondrial-specific rhodacyanine dye analog MKT 077.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(1):42-9.
2000: Eric K Rowinsky; R Humphrey; Lisa A Hammond; Cheryl Aylesworth; Leslie Ann Smetzer; Manuel Hidalgo; M Morrow; Lon Smith; A Garner; J M Sorensen; Daniel Von Hoff; S Gail Eckhardt
Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(1):178-86.
2000: Manuel Hidalgo; Miguel A Villalona-Calero; S Gail Eckhardt; Ronald L Drengler; G Rodriguez; Lisa A Hammond; Sami Diab; Geoffrey Weiss; A M Garner; Elizabeth Campbell; K Davidson; A Louie; J D O'Neil; R von Borstel; Daniel Von Hoff; Eric K Rowinsky
Phase I and pharmacologic study of PN401 and fluorouracil in patients with advanced solid malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(1):167-77.
1999: Miguel A Villalona-Calero; T Petit; John Kuhn; P Cobb; Maura Kraynak; S Gail Eckhardt; Ronald L Drengler; Cecilia Simmons; P Santabarbara; Daniel Von Hoff; Eric K Rowinsky
A phase I and pharmacological study of protracted infusions of crisnatol mesylate in patients with solid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(11):3369-78.
1999: John Nemunaitis; Jon T Holmlund; Maura Kraynak; D Richards; J Bruce; N Ognoskie; T Jesse Kwoh; Richard S Geary; Andrew Dorr; Daniel Von Hoff; S Gail Eckhardt
Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-alpha, in patients with advanced cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(11):3586-95.
1999: Manuel Hidalgo; Elzbieta Izbicka; S Gail Eckhardt; J R MacDonald; Cesario Cerna; Lionel Gomez; Eric K Rowinsky; Steven D Weitman; Daniel Von Hoff
Antitumor activity of MGI 114 (6-hydroxymethylacylfulvene, HMAF), a semisynthetic derivative of illudin S, against adult and pediatric human tumor colony-forming units.
Anti-cancer drugs 1999;10(9):837-44.
1999: Russell F DeVore; David H Johnson; Jeffrey Crawford; J Garst; I W Dimery; J Eckardt; S Gail Eckhardt; Gary L Elfring; Larry J Schaaf; CK Hanover; Langdon L Miller
Phase II study of irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(9):2710-20.
1999: Lisa A Hammond; John R Eckardt; Sharyn D Baker; S Gail Eckhardt; Margaret Dugan; K Forral; P Reidenberg; Paul Statkevich; Geoffrey R Weiss; David A Rinaldi; Daniel Von Hoff; Eric K Rowinsky
Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(8):2604-13.
1999: Carolyn D Britten; Eric K Rowinsky; Sharyn D Baker; S S Agarwala; John R Eckardt; RE Barrington; Sami Diab; Lisa A Hammond; T Johnson; Miguel A Villalona-Calero; U Fraass; Paul Statkevich; Daniel Von Hoff; S Gail Eckhardt
A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(7):1629-37.
1999: Miguel A Villalona-Calero; Geoffrey R Weiss; Howard A Burris; Maura Kraynak; G Rodrigues; Ronald L Drengler; S Gail Eckhardt; Bruno Reigner; Judy Moczygemba; Hans-Ulrich Burger; T Griffin; Daniel Von Hoff; Eric K Rowinsky
Phase I and pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(6):1915-25.
1999: S Gail Eckhardt; Jinee Rizzo; K R Sweeney; Gillian F Cropp; Sharyn D Baker; Maura Kraynak; John Kuhn; Miguel A Villalona-Calero; L Hammond; Geoffrey Weiss; A Thurman; Lon Smith; Ronald L Drengler; John R Eckardt; Judy Moczygemba; Alison L Hannah; Daniel Von Hoff; Eric K Rowinsky
Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(4):1095-104.
1999: Carolyn D Britten; Susan G Hilsenbeck; S Gail Eckhardt; Jennifer Marty; Gina L Mangold; John R MacDonald; Eric K Rowinsky; Daniel Von Hoff; Steven D Weitman
Enhanced antitumor activity of 6-hydroxymethylacylfulvene in combination with irinotecan and 5-fluorouracil in the HT29 human colon tumor xenograft model.
Cancer research 1999;59(5):1049-53.
1999: Sami Diab; Sharyn D Baker; A Joshi; Howard A Burris; P W Cobb; Miguel A Villalona-Calero; S Gail Eckhardt; Geoffrey R Weiss; Gladys I Rodriguez; Ronald L Drengler; Maura Kraynak; L Hammond; M Finizio; Daniel Von Hoff; Eric K Rowinsky
A phase I and pharmacokinetic study of losoxantrone and paclitaxel in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(2):299-308.
1999: S Gail Eckhardt
Angiogenesis inhibitors as cancer therapy.
Hospital practice (1995) 1999;34(1):63-8, 77-9, 83-4.
1999: David A Rinaldi; John Kuhn; Howard A Burris; F A Dorr; G Rodriguez; S Gail Eckhardt; Stephen E Jones; J R Woodworth; S Baker; C Langley; D Mascorro; T Abrahams; Daniel Von Hoff
A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation.
Cancer chemotherapy and pharmacology 1999;44(5):372-80.
1998: Eric K Rowinsky; Lon Smith; Y M Wang; P Chaturvedi; M Villalona; Elizabeth Campbell; Cheryl Aylesworth; S Gail Eckhardt; L Hammond; Maura Kraynak; Ronald L Drengler; Joseph Stephenson; M W Harding; Daniel Von Hoff
Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(9):2964-76.
1998: Russell F DeVore; D Johnson; Jeffrey Crawford; I Dimery; J Eckardt; S Gail Eckhardt
Irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer.
Oncology (Williston Park, N.Y.) 1998;12(8 Suppl 6):79-83.
1998: Mace L Rothenberg; John Kuhn; Larry J Schaaf; Ronald L Drengler; S Gail Eckhardt; Miguel A Villalona-Calero; L Hammond; Langdon L Miller; R G Petit; Eric K Rowinsky; Daniel Von Hoff
Alternative dosing schedules for irinotecan.
Oncology (Williston Park, N.Y.) 1998;12(8 Suppl 6):68-71.
1998: S Gail Eckhardt
Irinotecan: a review of the initial phase I trials.
Oncology (Williston Park, N.Y.) 1998;12(8 Suppl 6):31-8.
1998: Miguel A Villalona-Calero; Sharyn D Baker; L Hammond; Cheryl Aylesworth; S Gail Eckhardt; Maura Kraynak; Robert J Fram; Steven Fischkoff; R Velagapudi; D Toppmeyer; B Razvillas; K Jakimowicz; Daniel Von Hoff; Eric K Rowinsky
Phase I and pharmacokinetic study of the water-soluble dolastatin 15 analog LU103793 in patients with advanced solid malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(8):2770-9.
1998: Mace L Rothenberg; A Sharma; Geoffrey R Weiss; Miguel A Villalona-Calero; John R Eckardt; Cheryl Aylesworth; Maura Kraynak; David A Rinaldi; Gladys I Rodriguez; Howard A Burris; S Gail Eckhardt; CD Stephens; K Forral; S J Nicol; Daniel Von Hoff
Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumors.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998;9(7):733-8.
1998: Lisa A Hammond; John R Eckardt; R Ganapathi; Howard A Burris; G A Rodriguez; S Gail Eckhardt; Mace L Rothenberg; Geoffrey R Weiss; John Kuhn; S Hodges; Daniel Von Hoff; Eric K Rowinsky
A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposide.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(6):1459-67.
1998: S Gail Eckhardt; Sharyn D Baker; John R Eckardt; Thomas G Burke; D L Warner; John Kuhn; G Rodriguez; S Fields; A Thurman; Lon Smith; Mace L Rothenberg; L White; Paul Wissel; R Kunka; S DePee; D Littlefield; Howard A Burris; Daniel Von Hoff; Eric K Rowinsky
Phase I and pharmacokinetic study of GI147211, a water-soluble camptothecin analogue, administered for five consecutive days every three weeks.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(3):595-604.
1998: Lillian L Siu; Daniel Von Hoff; A Rephaeli; Elzbieta Izbicka; Cesario Cerna; Lionel Gomez; Eric K Rowinsky; S Gail Eckhardt
Activity of pivaloyloxymethyl butyrate, a novel anticancer agent, on primary human tumor colony-forming units.
Investigational new drugs 1998;16(2):113-9.
1997: Geoffrey R Weiss; Howard A Burris; S Gail Eckhardt; Gladys I Rodriguez; Sunil Sharma; A Valley
New anticancer agents.
Cancer chemotherapy and biological response modifiers 1997;17():178-94.
1997: S Gail Eckhardt; J M Pluda
Development of angiogenesis inhibitors for cancer therapy.
Investigational new drugs 1997;15(1):1-3.
1996: S Gail Eckhardt; Howard A Burris; John R Eckardt; G Weiss; G Rodriguez; M Rothenberg; David A Rinaldi; R Barrington; John Kuhn; K Masuo; K Sudo; R Atsumi; T Oguma; L Higashi; S Fields; Leslie Ann Smetzer; Daniel Von Hoff
A phase I clinical and pharmacokinetic study of the angiogenesis inhibitor, tecogalan sodium.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1996;7(5):491-6.
1996: Mace L Rothenberg; John R Eckardt; John Kuhn; Howard A Burris; James Nelson; Susan G Hilsenbeck; Gladys I Rodriguez; A M Thurman; L S Smith; S Gail Eckhardt; G R Weiss; Gary L Elfring; David A Rinaldi; Larry J Schaaf; Daniel Von Hoff
Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(4):1128-35.
1996: G R Weiss; H A Burris 3rd; John R Eckardt; S Gail Eckhardt; S M Fields; T O'Rourke; Gladys I Rodriguez; Mace L Rothenberg; A J Valley
New anticancer agents.
Cancer chemotherapy and biological response modifiers 1996;16():132-67.